BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed ABVX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:674c25ba707051a27af6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ABVX P2 readout (est.): ENHANCE-CD
DESCRIPTION:Efficacy and Safety of Obefazimod in Subjects With Moderately t
 o Severely Active Crohn's Disease\nNCT06456593 | PHASE2 | RECRUITING | spo
 nsor: Abivax S.A.\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nDate precision: month (shown on the first day)\nTic
 ker ABVX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT064
 56593\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06456593
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
